Bifidobacterium animalis and application thereof in allergic rhinitis products

By applying Bifidobacterium lactis subsp. Def+ bacterial agent, the immune imbalance in patients with allergic rhinitis is regulated, and the symptoms of allergic rhinitis are significantly improved. This solves the safety and treatment cycle problems of existing treatment methods and achieves safe and long-lasting therapeutic effects.

CN121450540APending Publication Date: 2026-02-03ZHONGKE WISBIOM(BEIJING)BIOTECHNOLOGY CO LTD

Patent Information

Application Number
CN202511916296.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-12-18
Publication Date
2026-02-03

AI Technical Summary

Technical Problem

Existing treatments for allergic rhinitis cannot meet patients' needs for safety, long-term efficacy, and treatment duration. The treatment duration in relevant patent literature is about 28 days, while the non-patent literature provides Bifidobacterium animalis subsp. lactis A6, which can only significantly improve nasal congestion and runny nose symptoms, but has no significant improvement on sneezing and nasal itching symptoms.

Method used

Using Bifidobacterium animalis subsp. lactis Def+, bacterial agents including bacterial cells, fermentation broth, fermentation broth supernatant, and lyophilized powder are prepared for the prevention and/or treatment of allergic rhinitis, regulating the Th1/Th2 balance, reducing serum IgE and IL-13 levels, and reducing inflammation of the nasal septum mucosa.

Benefits of technology

It significantly relieves symptoms of allergic rhinitis, including reducing the number of sneezes, nasal itching, the number and thickness of inflammatory cells in the nasal septum mucosa, reducing serum IgA and IgE, IL-4, IL-5, and IL-13 concentrations, restoring spleen index, and improving Th1/Th2 and Th17/Treg imbalances. Its safety profile is superior to dexamethasone.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121450540A_ABST
    Figure CN121450540A_ABST
Patent Text Reader

Abstract

The invention discloses bifidobacterium animalis and application thereof in allergic rhinitis products, and belongs to the technical field of microorganisms. The technical problem to be solved is that the existing common allergic rhinitis treatment means cannot meet the requirements of patients on safety, long-acting effect and treatment cycle. The invention provides an animal bifidobacterium subsp. Lactis Def +, and after an effective dose of animal bifidobacterium subsp. Lactis Def + is applied to a subject, the animal bifidobacterium subsp. Lactis Def + is found to be capable of remarkably relieving the allergic rhinitis symptom. Specifically, the symptoms of sneezing, dry nose and rhinocnesmus are reduced; the number of nasal septum mucosa intrinsic layer inflammation infiltration cells and nasal septum mucosa epithelium pathological changes are reduced; the IgA and IgE levels of serum are reduced; the levels of proinflammatory factors IL-4, IL-5 and IL-13 are reduced; the normal spleen index is maintained; the imbalance state of Th1 / Th2 and Th17 / Treg is effectively improved, and the body immunity is improved; a safe and long-acting scheme is provided for allergic rhinitis diseases.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The application belongs to the technical field of microorganisms, and particularly relates to an animal bifidobacterium and application of the animal bifidobacterium in an allergic rhinitis product. BACKGROUND

[0002] For understanding the technical content of the application: Allergic rhinitis (AR) is a global high-incidence result of the joint action of genetics and environment (allergens), and its main clinical manifestations are nasal itching, nasal congestion, sneezing, etc. Chronic nasal mucosal inflammatory diseases are mainly caused by type I hypersensitivity mediated by immunoglobulin E (IgE). After the allergen enters the nasal cavity, it is taken up by dendritic cells and presented to initial T cells, prompting them to differentiate into Th2 type, and secrete IL-4, IL-5, IL-13 and other cytokines, inducing B cells to produce specific IgE. IgE binds to the surface of mast cells and basophils FcεRI, and when exposed to allergens again, it causes cell degranulation, releasing histamine, leukotrienes and other inflammatory mediators, leading to nasal mucosal vascular dilation, increased gland secretion and increased nerve sensitivity. Studies have shown that AR is not only an excessive Th2 response, but also a Treg cell function defect, an insufficient Th1 response and an excessive activation of Th17 cells, forming a complex immune imbalance network. Treg cells secrete IL-10 and TGF-β, which have the effect of inhibiting Th2 response, and their functional defects are closely related to the chronicity of AR.

[0003] The commonly used treatment methods for allergic rhinitis at the present stage are: nasal hormones / antihistamines only control symptoms, long-term medication is needed, and there is a risk of mucosal damage and systemic side effects (such as growth inhibition in children); immunotherapy has a long cycle (2-3 years) and high cost, and is only suitable for single allergen and may induce severe allergic reactions; it is difficult to completely avoid allergens in practice (such as dust mites and pollen); due to cost or dose limitations, omalizumab is unlikely to be widely used for the treatment of allergic rhinitis; the essence of traditional Chinese medicine treatment of allergic rhinitis is the contradiction between its "individualization, slow conditioning" characteristics and "modern fast-paced, standardized medical needs". The needs of modern allergic rhinitis patients have not been met, and safe, long-acting, mechanism-innovative causal treatment methods are urgently needed to treat allergic rhinitis from the root of immune imbalance.

[0004] In recent years, the 'gut-nose axis' theory has gradually attracted attention. Studies have found that AR patients have reduced intestinal flora diversity, reduced beneficial bacteria such as Bifidobacterium and Lactobacillus, and increased potential pathogenic bacteria such as Escherichia coli and Staphylococcus aureus. Intestinal flora indirectly affects the immune status of the nasal mucosa by producing short-chain fatty acids (SCFAs), regulating Treg differentiation, and systemic inflammatory response. Animal experiments have shown that supplementing specific probiotics can restore Th1 / Th2 balance, reduce serum IgE and IL-13 levels, and significantly alleviate allergic rhinitis symptoms.

[0005] Allergic rhinitis, as a chronic immune imbalance disease, its treatment is changing from'symptom control' to 'immune regulation' and'microecological intervention'. Probiotics, with their safety, mildness, and multiple target advantages, provide a new path for individualized and green treatment of AR. With the deepening of the 'gut-nose axis' theory and the development of microecological technology, probiotics are expected to become an important part of AR comprehensive management.

[0006] Retrieved relevant patent documents: A strain of animal Bifidobacterium lactis subsp. lactis is disclosed in CN120285020A, published on July 11, 2025. This strain has good intestinal pathogenic bacteria inhibition ability, can balance the intestinal flora, restore and maintain the normal function of the immune system, regulate serum allergic markers and cytokine levels, regulate spleen CD4+ T lymphocyte differentiation, reduce nasal mucosa damage caused by allergy, and effectively improve allergic rhinitis symptoms. Bifidobacterium animalis subsp. lactis BGI N3. This strain has good intestinal pathogenic bacteria inhibition ability, can balance the intestinal flora, restore and maintain the normal function of the immune system, regulate serum allergic markers and cytokine levels, regulate spleen CD4+ T lymphocyte differentiation, reduce nasal mucosa damage caused by allergy, and effectively improve allergic rhinitis symptoms.

[0007] Retrieved relevant non-patent documents: Clinical and translational allergy, document name A6 alleviates perennial allergic rhinitis in adults by inhibiting serum total IgE and IL-13: A randomized, double-blind, placebo-controlled trial, volume vol. 15, 6 (2025): e70064, published on June 15, 2025. This document discloses that animal Bifidobacterium lactis subsp. lactis A6 can significantly alleviate the symptoms of adult perennial AR and improve the quality of life. Bifidobacterium animalis subsp. lactis The prior art represented by the foregoing documents has at least the following unsolved technical problems or defects:

[0008] ​The treatment cycle of the related patent document is about 28 days, while the present application only needs 21 days.

[0009] The related non-patent document provides that the animal bifidobacterium lactis A6 can significantly improve the symptoms of nasal congestion and runny nose, but has no obvious improvement on the symptoms of sneezing and nasal itching. SUMMARY

[0010] The present application aims to provide: An animal bifidobacterium and its application in allergic rhinitis products, and related technologies, to solve the technical problems or combinations that the current commonly used allergic rhinitis treatment methods cannot meet the needs of patients for safety, long-acting and treatment cycle.

[0011] Explanation of terms: Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the subject matter of the claims belongs. All patents, patent applications, publications, and other documents referenced herein are hereby incorporated by reference in their entirety unless otherwise indicated. In the event that there is a plurality of definitions for a term herein, those in this section prevail.

[0012] It should be understood that the above brief description and the following detailed description are exemplary and are intended to explain, but not limit, the subject matter of the present application. In the present application, the singular also includes the plural unless otherwise specified. It should also be noted that, unless otherwise specified, "or" and "or" are used to mean "and / or". In addition, the term "comprise" and other forms, such as "include", "contain" and "contain", are not limiting.

[0013] The definition of standard chemical terms can be found in the reference "Microbiology, Higher Education Press, Shen Ping, Chen Xiangdong, ed.".

[0014] Unless otherwise specified, conventional methods within the scope of the art are used, such as 16S rRNA gene sequencing method, API-50 carbon source utilization identification method and other methods.

[0015] Unless a specific definition is provided, the use of each type of commercially available product used herein uses standard technology. For example, the manufacturer's instructions for using the kit can be used, or the implementation can be carried out according to the way known in the art or the description of the present application. Generally, the above-mentioned technology and method can be implemented according to the description in the multiple summary and more specific literature cited and discussed in the present specification, according to the conventional method well known in the art.

[0016] The term "optionally" or "optionally" means that the event or circumstance described thereafter can or can not occur, and the description includes the occurrence of the event or circumstance and the non-occurrence of the event or circumstance. For example, according to the definition below, "a product optionally containing an adjuvant" means "a product not containing an adjuvant" (a product containing only a strain or a bacterial agent) or "a product containing an adjuvant" (a product containing a strain or a bacterial agent and at least one adjuvant).

[0017] The term "bacterial agent" used herein refers to a preparation containing live, dead or fermented liquid of Bifidobacterium animalis lactis Def+, which can be in the form of freeze-dried powder, capsule, granule, tablet or liquid.

[0018] The term "CFU" used herein refers to Colony-Forming Unit, which refers to the number of units of microorganisms that can grow and reproduce to form individual visible colonies on solid culture medium, and is often used to quantify the number of live microorganisms such as probiotics. The unit can be expressed as CFU / mL (liquid sample) or CFU / g (solid sample). In the present application, the determination of the number of live bacteria in the strain culture, bacterial agent and product is carried out by gradient dilution and plating method. After dilution, the sample is plated on MRS agar medium and incubated at 37°C anaerobically for 48h. The number of colonies is counted, and the CFU value is calculated by combining the dilution factor, for example, "1×10 10 CFU / mL" means that there are 10 10 live bacteria that can form colonies per milliliter of sample.

[0019] In one aspect, the present application provides a Bifidobacterium animalis lactis Def+, which has a preservation number of CGMCC No. 35798.

[0020] In another aspect, the present application provides a bacterial agent, which comprises the above-mentioned Bifidobacterium animalis lactis Def+.

[0021] The bacterial agent comprises one or more of the following: live bacteria, fermented liquid, supernatant of fermented liquid, precipitate of fermented liquid, freeze-dried powder of Bifidobacterium animalis lactis Def+.

[0022] The bacterial agent further comprises a nutritionally acceptable nutritional additive.

[0023] The nutritional additive includes, but is not limited to, any one or more of the following: dietary fiber, prebiotic, protein, lipid substance, mineral, vitamin.

[0024] In another aspect, the present application provides the use of the above-mentioned Bifidobacterium animalis lactis Def+ in the preparation of a product for preventing and / or treating allergic rhinitis.

[0025] The use includes any one or more of the following: (1) reducing the symptom of nasal itching and the number of sneezing caused by allergic rhinitis; (2) reducing the number of inflammatory cells in the lamina propria of the nasal septum mucosa; (3) reducing the thickness of the nasal septum mucosa epithelium; (4) reducing the concentration of IgA and IgE in serum; (5) reducing the concentration of IL-4, IL-5 and IL-13 in serum; (6) reducing the volume of germinal center in spleen; (7) maintaining the spleen index; (8) improving the imbalance state of Th1 / Th2 and Th17 / Treg caused by allergic rhinitis.

[0026] Preferably, the application is any one or more of the following: (1) preventing and / or treating seasonal allergic rhinitis; (2) preventing and / or treating perennial allergic rhinitis; (3) preventing and / or treating occupational allergic rhinitis; (4) preventing and / or treating drug-induced allergic rhinitis; (5) preventing and / or treating atopic rhinitis.

[0027] Preferably, the allergic rhinitis has the following characteristics: (1) nasal itching; (2) increased number of sneezing; (3) increased number of inflammatory cells in the lamina propria of the nasal septum mucosa; (4) increased thickness of the nasal septum mucosa epithelium; (5) increased concentration of IgA and IgE in serum; (6) increased concentration of IL-4, IL-5 and IL-13 in serum; (7) increased volume of germinal center in spleen; (8) decreased spleen index; (9) imbalance of Th1 / Th2 and Th17 / Treg.

[0028] In another aspect, the present application provides a product with the function of preventing and / or treating allergic rhinitis, which comprises the animal Bifidobacterium lactis Def+ or any of the above bacterial agents.

[0029] Preferably, the product contains at least 1×10 8 CFU / mL of animal Bifidobacterium lactis Def+.

[0030] Preferably, the dosage form of the product includes liquid, gas, solid or semi-solid.

[0031] The dosage form of the product includes, but is not limited to, liquid solution, lyophilized powder, tablet, capsule, granule, spray, oral dispersible tablet / film, sublingual tablet / lozenge, gel, cream / ointment, suppository, in-situ gel, compound preparation or child-friendly (flavored granules, oral drops).

[0032] The product includes pharmaceuticals, food, compound products and animal feed additives.

[0033] The pharmaceuticals include, but are not limited to, live bacterial preparations, inactivated bacterial preparations, bacterial lysates, bacterial powders, etc. for preventing and / or treating allergic rhinitis. They can be prepared into oral dosage forms such as capsules, tablets, granules and powders.

[0034] The food includes, but is not limited to, health foods, dietary supplements and ordinary foods.

[0035] The health foods and / or dietary supplements take Bifidobacterium animalis lactis Def+ as the core functional ingredient and are added to probiotic supplements, probiotic capsules and probiotic powders.

[0036] The ordinary foods include, but are not limited to, drinks, dairy products, solid snacks and fermented foods.

[0037] The drinks include, but are not limited to, at least one of probiotic beverages, lactic acid bacteria beverages and fruit juices.

[0038] The dairy products include, but are not limited to, at least one of yogurt, fermented milk, cheese and ice cream.

[0039] The solid snacks include probiotic biscuits, probiotic cereals and probiotic pastries.

[0040] The fermented foods include, but are not limited to, probiotic fermented soy products and probiotic fermented cereal products.

[0041] The compound product is a "synbiotic" product formed by combining Bifidobacterium animalis lactis Def+ with prebiotics (such as fructooligosaccharides and inulin) or other probiotics or natural products (such as perilla seed extract) with anti-allergic function to achieve synergistic effect.

[0042] The animal feed additive is used for preventing allergic diseases of pets (such as cats and dogs).

[0043] The product further includes excipients.

[0044] The adjuvant includes, but is not limited to, any one or more of diluents, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, co-solvents, solubilizers, osmotic pressure adjusting agents, surfactants, coating materials, coloring agents, pH adjusting agents, antioxidants, and buffers.

[0045] The product can be administered orally, topically, by spray, by inhalation, or a combination thereof.

[0046] In another aspect, the present application provides a method for treating a disease, comprising administering to a subject an effective amount of Bifidobacterium animalis lactis Def+.

[0047] The disease is allergic rhinitis.

[0048] The allergic rhinitis includes, but is not limited to, seasonal allergic rhinitis, perennial rhinitis, occupational allergic rhinitis, drug-induced allergic rhinitis, or atopic rhinitis.

[0049] The term "subject" includes a living organism (e.g., a mammal) that can elicit an immune response. Examples of subjects include humans, primates, cows, horses, goats, sheep, dogs, cats, mice, rats, rabbits, guinea pigs, pigs, and transgenic species thereof.

[0050] The term "treat" or "ameliorate" refers to the medical management of a disease, disorder, or undesirable condition in a subject. Therapeutic or prophylactic benefit includes improved clinical outcome; reduction or alleviation of symptoms associated with the disease, disorder, or undesirable condition; diminishment of a symptom occurrence; improved quality of life; longer disease-free status; reduction in extent of disease, disorder, or undesirable condition; stabilization of disease state; delay of disease progression; remission; survival; prolonged survival; or any combination thereof.

[0051] The term "therapeutically effective amount" refers to a dosage of a drug that is considered pharmaceutically effective, i.e., an amount of active drug sufficient to significantly improve the condition without producing serious side effects. The dosage depends on many factors, such as the nature and severity of the disease to be prevented or treated, the gender, age, weight, character, and individual response of the patient or animal, the route of administration, the number of administrations, the purpose of the treatment, and thus the dosage of the present application can vary widely.

[0052] The present application has at least the following beneficial effects: (1) Strain Def+ can significantly alleviate the symptoms of allergic rhinitis, including reducing the number of sneezing, scratching nose, the number of inflammatory cells in the nasal septum mucosa lamina propria, the thickness of the nasal septum mucosa epithelium, the concentration of serum IgA and IgE, inflammatory factors IL-4, IL-5, IL-13 and the volume of germinal center in the spleen, and improve the imbalance state of Th1 / Th2 and Th17 / Treg caused by allergic rhinitis; (2) Strain Def+ has no adverse reactions during treatment, and its safety is higher than that of dexamethasone; (3) The spleen index of strain Def+ returns to normal level, indicating that its regulation on immune system is more moderate and has no risk of immune suppression.

[0053] DEPOSIT INFORMATION Deposit strain: Bifidobacterium animalis lactis Def+; Classification name: Bifidobacterium animalis lactis Bifidobacterium animalis subsp. lactis ; Deposit number: CGMCC No.35798; Deposit time: September 02, 2025; Deposit unit: China General Microbiological Culture Collection Center; Deposit address: No.3, Beichen West Road, Chaoyang District, Beijing. BRIEF DESCRIPTION OF DRAWINGS

[0054] Figure 1 The number of sneezing of each group of experimental animals after the last challenge is counted.

[0055] Figure 2 The number of scratching nose of each group of experimental animals after the last challenge is counted.

[0056] Figure 3 The nasal septum mucosa HE staining sections of each group of experimental animals are shown.

[0057] Figure 4 The thickness of the nasal septum mucosa epithelium of each group of experimental animals is counted, * represents P <0.05, **** represents P <0.0001.

[0058] Figure 5 The number of nucleated cells in the lamina propria of the nasal septum mucosa of each group of experimental animals is counted, ** represents P <0.01, **** represents P <0.0001.

[0059] Figure 6 The concentration of IgA in the serum of each group of experimental animals is counted, * represents P <0.05, **** representsP <0.0001.

[0060] Figure 7 Statistical analysis of IgE concentration in serum of experimental animals in each group, NS represents P ≥ 0.05, *** represents P <0.001, **** represents P <0.0001.

[0061] Figure 8 Statistical analysis of IL-4 concentration in serum of experimental animals in each group, NS represents P ≥ 0.05, **** represents P <0.0001.

[0062] Figure 9 Statistical analysis of IL-5 concentration in serum of experimental animals in each group, NS represents P ≥ 0.05, *** represents P <0.001, **** represents P <0.0001.

[0063] Figure 10 Statistical analysis of IL-13 concentration in serum of experimental animals in each group, NS represents P ≥ 0.05, **** represents P <0.0001.

[0064] Figure 11 Spleen HE staining sections of experimental animals in each group.

[0065] Figure 12 Statistical analysis of spleen index of experimental animals in each group, NS represents P ≥ 0.05, ** represents P <0.01, *** represents P <0.001, **** represents P <0.0001.

[0066] Figure 13 Statistical analysis of Th1 / Th2 ratio of spleen cells of experimental animals in each group, NS represents P ≥ 0.05, *** represents P <0.001, **** represents P <0.0001.

[0067] Figure 14 Statistical analysis of Th17 / Treg ratio of spleen cells of experimental animals in each group, NS represents P ≥ 0.05, *** represents P <0.001, **** represents P <0.0001.

[0068] Figure 15 Results of intervention of allergic rhinitis volunteers by Def+ strain. DETAILED DESCRIPTION

[0069] Unless otherwise indicated, all materials and reagents used in the present application were purchased from commercial suppliers and used according to the manufacturer's instructions. Unless otherwise indicated, the instruments, equipment, devices, etc. used in the present application are conventional instruments, equipment, devices, etc. and are used according to the manufacturer's instructions and the supporting reagents.

[0070] In order to make the purpose, technical solutions and advantages of the present application clearer and more apparent, the present application will be further described in detail below in combination with examples. If the specific conditions are not specified in the examples, the experiments are carried out according to the conventional conditions or the conditions recommended by the manufacturer. If the manufacturers of all reagents or instruments are not specified, they are all conventional products that can be purchased on the market. In order to better illustrate the present application, numerous specific details are given in the specific embodiments below. The specific embodiments described herein are only used to explain the present application and do not constitute any limitation on the present application.

[0071] Example 1 Preparation of bacterial powder The strain was subcultured and activated at 37°C for 3 times using MRS medium, and then the bacterial liquid was inoculated into MRS liquid medium for expansion culture (the culture volume was determined according to the actual demand), and the culture conditions were as follows: 37°C static culture for 16h, and the culture liquid of the strain was obtained; The obtained bacterial liquid was centrifuged at 6000g for 5min, and the supernatant was discarded. The bacterial slurry and skimmed milk were mixed at a mass ratio of 1:1, and then mixed uniformly and placed in a freeze dryer for vacuum freeze drying. After vacuum freeze drying for 48h, the bacterial powder was obtained.

[0072] Example 2 Improvement of allergic rhinitis by Bifidobacterium animalis lactis Def+ 1. Animal experiment specific implementation: The experimental animals are 6-week-old SPF grade BABL / c female mice, which are raised in a 23±2°C, 12h day-night cycle lighting environment, with free access to food and water. The main reagents are high-purity ovalbumin (OVA, purchased from MCE, CAS No.: 9006-59-1), aluminum hydroxide (purchased from MCE, CAS No.: 21645-51-2) and dexamethasone (Dex, purchased from MCE, CAS No.: 50-02-2). The intraperitoneal sensitization reagent is to add OVA to a 2.5% aluminum hydroxide saline solution to make the OVA concentration 0.25%; the allergic rhinitis challenge reagent is a 2% OVA saline solution. The animal experiment sets up a blank group, a model group, a Dex treatment group, an animal Bifidobacterium lactis subspecies I90-601 group (the I90-601 strain is isolated from breast milk by the inventor and preserved, and is the same batch of isolated strain as Def+), and an animal Bifidobacterium lactis subspecies Def+ group, each group of 8 mice, and the strains are separately administered to the mice by gavage.

[0073] The animal gavage and sensitization reagent information is shown in Table 1.

[0074] Table 1. Animal gavage, sensitization and challenge reagents

[0075] 2. Strain intervention animals: The mice are gavaged from the first day of the experiment, with a daily gavage strain concentration of 1×10 10 CFU / mL, with a gavage dose of 100 μL per mouse per day. The first 14 days of the experiment are the sensitization stage, and the mice are sensitized on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th day, with a sensitization dose of 200 μL per mouse; the 15th to 21st day of the experiment is the challenge stage, and the mice are challenged by nasal instillation every day, with a challenge dose of 20 μL per mouse.

[0076] Detection index: After the last challenge, observe the sneezing and scratching nose behavior of the mice. The mice are killed 24 hours after the last challenge, and serum, nasal tissue and spleen are collected to detect 6 indexes such as IgE concentration in mouse serum, number of inflammatory cells in nasal septum mucosa, measurement of nasal septum epithelial thickness, calculation of spleen index, etc.

[0077] 3. Detection results 3.1 Mouse behavior statistics Scratching nose behavior: lifting the front or hind paws to scratch the nose and returning to the ground is counted as 1 time.

[0078] Sneezing behavior: slight tremor of the head or body, and at the same time hearing the sound of sneezing is counted as 1 time.

[0079] After the last challenge, the mice were placed in a clean cage, and after 5 min of adaptation, the sneezing and scratching behaviors of the mice were counted within 20 min. During the video recording period, the experimenter could not enter the mouse room, and the room was kept quiet. Figure 1 、 Figure 2 The results of the behavior statistics after the last challenge are shown in Table 2.

[0080] Compared with the model group, the number of sneezes of the blank, Dex treatment, and Def+ groups was lower than that of the model group, the number of sneezes of the I90-601 group was abnormally higher than that of the model group, the number of sneezes of the Def+ group and the Dex treatment group was lower than that of the model group, and was closer to that of the blank group. This shows that Def+ performs better than the I90-601 group, and Def+ can significantly reduce the number of sneezes of allergic rhinitis mice.

[0081] Compared with the model group, the number of scratches of the blank, Dex treatment, and Def+ groups was lower than that of the model group, and the number of scratches of the I90-601 group was slightly lower than that of the model group. The Def+ group was closer to the blank group, performed better than the Dex treatment group and the I90-601 group, and could effectively reduce the itching symptoms caused by allergic rhinitis.

[0082] 3.2 Histopathological observation of mouse nasal tissue Twenty-four hours after the last challenge, the nasal tissue was removed and decalcified, and then HE staining was performed to observe the nasal septum mucosa, with a magnification of 20x. The staining pictures of each group are shown in FIG. 6. Figure 3 The epithelial thickness of the nasal septum mucosa was measured using the software Slide Viewer, and the number of nucleated cells in the lamina propria was counted. The statistical results are shown in Table 3. Figure 4 、 Figure 5 .

[0083] The cilia of the nasal septum mucosa of the blank group were arranged in an orderly manner, the basal cell layer of the epithelial layer was clear, and there was no obvious inflammatory cell infiltration in the lamina propria. The cilia of the model group were arranged in disorder, the overall thickness of the epithelial layer was increased, the cells were arranged irregularly, there was a large amount of inflammatory cell infiltration in the lamina propria, and the small blood vessels were obviously dilated. The epithelial thickness of the nasal septum mucosa of the Dex treatment group was smaller than that of the model group, and the number of inflammatory cells infiltrating the lamina propria was smaller. The epithelial thickness of the nasal septum mucosa of the I90-601 group was slightly smaller than that of the model group, was larger than that of the blank group, the Dex group, and the Def+ group, and the inflammatory cell infiltration in the lamina propria was less. The cells of the epithelial layer of the Def+ group were arranged in an orderly manner, the inflammatory cell infiltration in the lamina propria was less, and the state of the nasal septum mucosa was close to that of the blank group.

[0084] Figure 4The nasal septum mucosa epithelium thickness of the hollow blank group, Dex treatment group and Def+ group was lower than that of the model group, and the difference was extremely significant (P<0.0001). The difference between the I90-601 group and the model group was significant (P<0.05). Def+ performed better than the Dex group, reduced the proliferation and edema of the nasal septum mucosa epithelium, reduced the damage of the allergic rhinitis to the nasal septum mucosa barrier, and resisted the further invasion of the allergen to the nasal septum mucosa.

[0085] Figure 5 The number of nasal septum mucosa nucleated cells of the hollow blank group, Dex treatment group and Def+ group was lower than that of the model group, and the difference was extremely significant (P<0.0001). The number of the I90-601 group was also lower than that of the model group, and the difference was very significant (P<0.01). Def+ can inhibit the activation, migration and aggregation of inflammatory cells by regulating the immune system of the mouse, thereby reducing the intensity of the local inflammatory reaction.

[0086] 3.3 Serological study of mice The eyeballs of experimental animals were taken for blood, and the blood was left to stand at room temperature for 1.5 h, centrifuged at 12000 r / min for 5 min, and the supernatant was taken and stored at -80℃ for standby.

[0087] 3.3.1 Mouse serum IgA Mouse IgA ELISA Kit, purchased from Thermo Scientific, item number EMIGAX5. Refer to the kit instruction for operation steps, measure the OD value of each well at OD450nm wavelength, record and then perform statistical analysis, and the statistical results are shown in Table 3. Figure 6

[0088] The serum IgA level of the blank group mice was lower than that of the model group, and the difference was extremely significant (P<0.0001). The serum IgA of the Dex treatment group and the Def+ group mice was lower than that of the model group, and the difference was extremely significant (P<0.0001). The serum IgE of the I90-601 group mice was different from that of the model group (P<0.05). Def+ can significantly reduce the IgA level in the serum of allergic rhinitis mice, and effectively relieve the mucosal immune response.

[0089] 3.3.2 Mouse serum IgE Mouse IgE ELISA Kit, purchased from Solarbio, item number: SEKM-0345. Refer to the kit instruction for operation steps, measure the OD value of each well at OD450nm wavelength, record and then perform statistical analysis, and the statistical results are shown in Table 4. Figure 7

[0090] ​​The serum IgE level of the blank group mice was lower than that of the model group, and the difference was extremely significant (P<0.0001). The serum IgE level of the Dex treatment group and the Def+ group mice was lower than that of the model group, and the difference was particularly significant (P<0.001). The serum IgE level of the I90-601 group mice had no significant difference with that of the model group. Def+ can significantly reduce the IgE level in the serum of allergic rhinitis mice and improve the anti-allergic ability of the body.

[0091] 3.3.3 Serum IL-4 of Mice Mouse IL-4 (Interleukin 4) ELISA Kit, High Sensitivity, purchased from Sangon, item number: D725504. Refer to the kit instruction for operation steps, measure the OD value of each well at the wavelength of OD450nm, record it and then perform statistical analysis, and the statistical results are shown in Table 3.3.3. Figure 8

[0092] The results show that the serum IL-4 level of the model group is significantly higher than that of the blank group (p<0.0001), and the Dex treatment group and the Def+ group, and has no difference with the I90-601 group, indicating that the strain Def+ improves the anti-inflammatory ability of the body.

[0093] 3.3.3 Serum IL-5 of Mice Mouse IL-5 (Interleukin 5) ELISA Kit, High Sensitivity, purchased from Sangon, item number: D725505. Refer to the kit instruction for operation steps, measure the OD value of each well at the wavelength of OD450nm, record it and then perform statistical analysis, and the statistical results are shown in Table 3.3.3. Figure 9

[0094] The results show that the serum IL-5 level of the model group is significantly higher than that of the blank group and the Dex treatment group (p<0.0001), and higher than that of the Def+ group (p<0.001), and has no difference with the I90-601 group, indicating that the strain Def+ improves the anti-inflammatory ability of the body.

[0095] 3.3.4 Serum IL-13 of Mice Mouse IL-13 ELISA Kit, purchased from Thermo Scientific, item number: BMS6015. Refer to the kit instruction for operation steps, measure the OD value of each well at the wavelength of OD450nm, record it and then perform statistical analysis, and the statistical results are shown in Table 3.3.4. Figure 10

[0096] ​​​The results showed that the serum IL-13 level of the model group was significantly higher than that of the blank group, Dex treatment group and Def+ group (p<0.0001), and there was no difference between the model group and the I90-601 group, indicating that the strain Def+ improved the body's anti-inflammatory ability.

[0097] 3.4 Spleen pathological study of mice After HE staining of the mouse spleen, the spleen state of each group of mice was observed. The magnification was 5x, and the spleen section was as shown in Figure 11 .

[0098] The boundary between the white pulp and the red pulp of the blank group was clear, and the dense lymphocytes were gathered in the white pulp. The blood cells were uniformly distributed in the red pulp, showing the normal state of the spleen. The boundary between the white pulp and the red pulp of the model group was blurred, the white pulp area increased, and the germinal center (light staining area) area increased significantly. The white pulp area of the Dex group decreased significantly, and the germinal center almost disappeared. The normal ratio of the red pulp and the white pulp was broken, and the overall tissue structure of the spleen was relatively loose, and the tightness between cells decreased. The germinal center of the I90-601 group increased significantly, and the spleen state was close to that of the model group. The boundary between the white pulp and the red pulp of the Def+ group was clear, and the germinal center area size was close to that of the blank group.

[0099] The abnormal state of the spleen of the Dex group reflected that Dex had damaged the immune organs of the body. The spleen structure of the Def+ group was relatively complete, indicating that the strain had a better effect on maintaining the normal tissue structure of the spleen, and was helpful to maintain the normal immune function of the spleen. And the ratio of the red pulp and the white pulp of the Def+ group was closer to normal, indicating that the strain had more advantages in regulating the overall immune microenvironment of the spleen, was safer, and was suitable for long-term taking.

[0100] 3.5 Spleen index After the last challenge for 24h, each mouse was weighed, and the spleen was collected and weighed after the mouse was killed. The spleen index was calculated, and the spleen index (mg / g) = spleen weight (mg) / body weight (g). The detection results are shown in Figure 12 .

[0101] The spleen index of the blank group was lower than that of the model group, and the difference was very significant (P<0.001). The spleen index of the Dex group was abnormally low, and there was no significant difference between the I90-601 group and the model group. The difference between the Def+ group and the model group was very significant (P<0.01), and the spleen index was closer to that of the blank group.

[0102] The spleen index of the Dex group mouse was less than 2mg / g, which was lower than the normal range. Dex is a glucocorticoid drug, and glucocorticoids can activate the intracellular apoptosis signaling pathway, leading to massive death of lymphocytes in the spleen, especially the killing effect on T cells is more significant. The decrease in the number will directly lead to the decrease in the weight of the spleen, and the side effects of Dex will inhibit the immune system.

[0103] 3.6 Spleen immune cell research Mouse helper Th1 / Th2 cell detection kit and mouse helper Th17 cell detection kit were purchased from MULTI SCIENCES, item number: KTH201 and KTH217. The operation steps refer to the kit instructions. The number of mouse spleen helper T cells was detected by flow cytometry, and the Th1 / Th2 and Th17 / Treg ratios were calculated. Statistical analysis, and the statistical results are shown in Table 2, and the difference score results of each group and the model group are shown in Table 2. Figure 13 and Figure 14 .

[0104] The results show that compared with the blank group, the Th1 / Th2 cell number ratio of the model group is significantly reduced (p<0.0001), and the Th17 / Treg ratio is significantly increased (p<0.0001), indicating that allergic rhinitis leads to Th1 / Th2 imbalance, biasing T cell-mediated humoral immunity, promoting B cell antibody production, especially IgE antibody; compared with the blank group, the model group is Th17 / Treg imbalance, biasing Th17 to participate in host defense and inflammatory response, promoting inflammation. Compared with the model group, the strain Def+ group can effectively improve the Th1 / Th2 and Th17 / Treg imbalance state (P<0.001), improve the immune state, reduce the degree of inflammation, and improve the body's anti-allergic ability.

[0105] 3.6 Detection index summary The animal experiment sets blank, model, Dex treatment groups, and sets 2 strains to intervene in each group of mice by gavage. After the last challenge, observe the sneezing and scratching nose behavior of mice. 24 hours after the last challenge, the mice were killed, and serum, nasal tissue and spleen were collected. The concentration of IgA, IgE, IL-4, IL-5 and IL-13 in mouse serum was detected, the number of inflammatory cells in the nasal septum mucosa was counted, the thickness of the nasal septum mucosa was measured, the nasal septum mucosa and spleen tissue were observed by pathology, the spleen index was calculated, the spleen cells were detected and the Th1 / Th2 and Th17 / Treg ratios were calculated. The difference between the indexes of each group and the model group is shown in Table 2, and the difference score results of each group and the model group are shown in Table 2.

[0106] The indexes of the blank group were lower than those of the model group, and there was a significant difference (p<0.0001), which indicated that the allergic rhinitis mouse model was successfully established. The indexes of the Dex treatment group were significantly different from those of the model group (p<0.0001), but the spleen index was abnormally low compared with the blank group, which indicated that Dex had an immunosuppressive effect on the mouse body while treating allergic rhinitis, and the mouse body weight decreased seriously, the body was emaciated, and the side effects were large. Only three indexes of the I90-601 group were different from those of the model group, two of which (p<0.05) and one of which (p<0.01), and the other indexes had no significant difference from those of the model group. The sneezing frequency was abnormally high than that of the model group, which could be considered as having no therapeutic effect on allergic rhinitis. All the indexes of the Def+ group were significantly different from those of the model group, seven indexes (p<0.0001), four indexes (p<0.001), and one index (p<0.01). The strain had a good effect on allergic rhinitis, which was specifically manifested as follows: reducing the sneezing and scratching nose frequencies; reducing the number of inflammatory infiltrating cells in the nasal septum mucosa and the thickness of the nasal septum mucosa epithelium; reducing the serum IgA and IgE immune protein concentration levels; reducing the related pro-inflammatory factor IL-4, IL-5, and IL-13 concentration levels; reducing the germinal center volume in the spleen, and the spleen index returned to the normal level. The safety was higher than that of dexamethasone; effectively improving the Th1 / Th2 and Th17 / Treg imbalance state, and improving the body immune ability.

[0107] Table 2: Statistical difference summary of each index and model group

[0108] Note: NS represents P ≥0.05,* P <0.05, ** P <0.01, *** P <0.001, **** P <0.0001; The sneezing frequency <61 was considered to alleviate the sneezing symptoms, that is, less than 2 / 3 times of the sneezing frequency of the model group. The scratching nose frequency <26 was considered to alleviate the scratching nose frequency, that is, less than 2 / 3 times of the scratching nose frequency of the model group.

[0109] Example 3: Strain intervention in allergic rhinitis population Strain preparation: After fermentation, centrifugation, and twice washing of the animal bifidobacterium lactis Def+, 10% skimmed milk powder was added as a protective agent, and vacuum freeze-drying was performed to prepare freeze-dried bacteria powder. Malt dextrin and freeze-dried bacteria powder were mixed according to a certain proportion to prepare a probiotic preparation, and the theoretical number of live bacteria was 1×10 10 CFU / g, the number of dead bacteria was 10-15% by fluorescent staining flow cytometry, 0.5 g / bag was packaged, and the storage environment was 2-8°C.

[0110] Volunteer recruitment: allergic rhinitis population, including pollen and grass pollen, dust mites, pet dander related allergic population.

[0111] Intervention method: 20 volunteers were randomly divided into 2 groups, respectively taking animal Bifidobacterium lactis Def+ strain preparation and malt dextrin placebo, 10 volunteers in each group, one bag in the morning and evening, continuous use for 30 days, strain warm water or ice water, observation of volunteers before and after intervention allergic symptoms.

[0112] Allergic rhinitis population nasal and nasal associated symptom score system reference table 3, volunteer score results refer to Figure 15 .

[0113] Table 3: nasal and nasal associated symptom score table

[0114] The results show that: there is no difference in the score of the placebo group before and after intervention, and the symptom score of the Def+ group after intervention is lower than that before intervention (P<0.0001), which shows that animal Bifidobacterium lactis Def+ strain can effectively reduce the nasal and nasal associated symptom score of allergic rhinitis population. The specific performance is that sneezing, runny nose and nasal congestion phenomenon is reduced; nasal, ocular, auricular and pharyngeal pruritus symptoms are reduced or disappeared; tearing, cough, headache and taste reduction phenomenon is reduced or disappeared.

[0115] Finally, it should be pointed out that the above content is only used to illustrate the technical solutions of the present application, and is not a limitation on the protection scope of the present application. Simple modification or equivalent replacement of the technical solutions of the present application by ordinary skilled in the art does not deviate from the essence and scope of the technical solutions of the present application.

Claims

1. A subspecies of Bifidobacterium lactis ( Bifidobacterium animalis subsp. lactis ), characterized in that, The animal bifidobacterium lactis subsp. is animal bifidobacterium lactis subsp. Def+, and the preservation number is CGMCC No. 35798.

2. An inoculant characterized in that, The bacterial agent includes the animal bifidobacterium lactis subsp. Def+ of claim 1.

3. The use of the animal bifidobacterium lactis subsp. Def+ of claim 1 or the bacterial agent of claim 2 in the preparation of a product for preventing and / or treating allergic rhinitis.

4. Use according to claim 3, characterized in that, Any one or more of the following applications: (1) reducing the symptoms of nasal itching and sneezing caused by allergic rhinitis; (2) reducing the number of inflammatory cells in the nasal septum mucosa lamina propria; (3) reducing the thickness of the nasal septum mucosa epithelium; (4) reducing the concentration of IgA and IgE in serum; (5) reducing the concentration of IL-4, IL-5, IL-13 in serum; (6) reducing the volume of germinal center in spleen; (7) maintaining the spleen index; (8) improving the imbalance of Th1 / Th2 and Th17 / Treg caused by allergic rhinitis.

5. Use according to claim 4, characterized in that, Any one or more of the following applications (1) preventing and / or treating seasonal allergic rhinitis; (2) preventing and / or treating perennial allergic rhinitis; (3) preventing and / or treating occupational allergic rhinitis; (4) preventing and / or treating drug-induced allergic rhinitis; (5) preventing and / or treating atopic rhinitis.

6. Use according to claim 3, characterized in that, The allergic rhinitis has the following characteristics: (1) nasal itching; (2) increased sneezing frequency; (3) increased number of inflammatory cells in the nasal septum mucosa lamina propria; (4) increased thickness of the nasal septum mucosa epithelium; (5) increased concentration of IgA and IgE in serum; (6) increased concentration of IL-4, IL-5, IL-13 in serum; (7) increased volume of germinal center in spleen; (8) decreased spleen index; (9) imbalance of Th1 / Th2 and Th17 / Treg.

7. A product having a function of preventing and / or treating allergic rhinitis, characterized by, The animal bifidobacterium lactis subsp. Def+ of claim 1 or the bacterial agent of claim 2.

8. The product of claim 7, wherein, The product comprises at least 1 x 10 8 CFU of animal Bifidobacterium lactis Def+.

9. The product of claim 7, wherein, The dosage form of the product includes solid dosage form, semi-solid dosage form or liquid dosage form.

10. The product of claim 7, wherein, The product includes excipients, which include any one or more of diluents, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, buffers.

Citation Information

Patent Citations

  • Application of bifidobacterium lactis BLa80 in improving and relieving anaphylactic reaction

    CN115518080A

  • Bifidobacterium lactis HC2786 capable of relieving anaphylactic reaction and product and application of bifidobacterium lactis HC2786

    CN116083323A

  • Application of bifidobacterium animalis subsp. Lactis in preparation of preparation for preventing and / or treating allergic rhinitis

    CN120285020A

Cited By

  • Bifidobacterium animalis for relieving eye allergy and application thereof

    CN121592551A

  • Strain for improving skin diseases as well as product and application thereof

    CN121931012A

  • Application of bifidobacterium animalis in relieving respiratory tract allergy symptoms

    CN122005620A